Key Highlights

  • Shares extended losses to 30.39% by Friday afternoon, deepening a decline that started in the morning session at around 24%.
  • The extended selloff reflects a broadening analyst response to the company's voluntary enrollment pause in its azetukalner studies for major depressive disorder and bipolar depression.
  • Multiple banks have now trimmed price targets on the stock, though most have maintained Outperform or Buy ratings, arguing the core epilepsy Franchise value remains intact.
  • The company's NDA submission for azetukalner in focal seizures, backed by strong Phase 2b/3 data, has not been affected by the psychiatric-program safety signal.

Selloff Deepens Through the Session

Xenon Pharmaceuticals (NASDAQ:XENE) shares extended their decline through Friday's session, falling as much as 30.39% by the afternoon after opening the day down roughly 24% following the company's disclosure of a voluntary pause in new patient enrollment for its azetukalner studies in major depressive disorder and bipolar depression. Xenon Pharmaceuticals is a Burnaby, British Columbia-based clinical-stage, neuroscience-focused biopharmaceutical company developing therapeutics for patients with neurological and psychiatric disorders.

Analyst Response Broadens as the Day Progresses

As the session progressed, a wider group of banks weighed in on the psychiatric-program setback, with several trimming price targets to reflect the added uncertainty around the delayed X-NOVA2 major depressive disorder readout, now pushed to the first quarter of 2027. Even so, most analysts have maintained Outperform or Buy ratings, arguing that the core epilepsy franchise value remains largely intact despite the psychiatric safety questions.

Epilepsy NDA Filing Remains Unaffected by the Safety Signal

Notably, the company's New Drug Application submission to the FDA for azetukalner in focal seizures, backed by strong Phase 2b/3 trial data, has not been affected by the enrollment pause, since the safety signal was isolated to the psychiatric-indication studies and is described by the company as consistent with the drug's known mechanism and expected to be temporary.